Please ensure Javascript is enabled for purposes of website accessibility

Better Coronavirus Stock: Novavax vs. Quidel

By Keith Speights – Aug 2, 2020 at 9:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Two very different companies with two very promising COVID-19 programs.

Every battlefront in the fight against COVID-19 is important. Novavax (NVAX -10.14%) is focused on developing a vaccine candidate that could potentially prevent infection by the novel coronavirus. Quidel (QDEL) makes COVID-19 diagnostics tests.

So far in 2020, Novavax has delivered more impressive gains. Its shares have skyrocketed over 3,500% compared to Quidel's solid gain of close to 277%. Which of these two coronavirus stocks is the better pick now? Here's how Novavax and Quidel compare.

Four people wearing white coats standing in a circle around a touchscreen tablet displaying "coronavirus"

Image source: Getty Images.

The case for Novavax

Novavax was viewed as a dark-horse candidate when the biotech first announced plans to develop an experimental COVID-19 vaccine earlier this year. Now, though, the company is a legitimate contender in the coronavirus vaccine race.

The clearest sign of just how serious of a contender Novavax might be came on July 7. That's when Operation Warp Speed, the U.S. government initiative to accelerate the development of COVID-19 vaccines, awarded $1.6 billion to Novavax. The money is targeted for the late-stage clinical testing of Novavax's COVID-19 vaccine candidate NVX-CoV2373 and for the production of 100 million doses of the experimental vaccine. 

Novavax plans to announce the results from the phase 1 portion of a phase 1/2 clinical study of NVX-CoV2373 this week. The phase 2 part of the study is expected to begin soon afterward. Novavax hopes to initiate a pivotal phase 3 study in the fall of 2020. 

But Novavax's COVID-19 vaccine candidate isn't the only reason why investors are excited about the biotech stock. The company also claims a very promising flu vaccine candidate, NanoFlu. Novavax announced overwhelmingly positive results for NanoFlu in March.

The next step for Novavax with regards to NanoFlu is to file for approval. If NanoFlu wins approval (as seems likely), it could generate peak sales of over $1 billion.

Novavax also two other clinical-stage pipeline candidates. Respiratory syncytial virus (RSV) vaccine candidate ResVax disappointed in previous late-stage studies. However, Novavax still thinks there could be a path to approval for the experimental vaccine. The company also completed phase 1 testing of an Ebola glycoprotein vaccine candidate. This candidate isn't in active development right now, though.

The case for Quidel

Quidel hit the ground running in March after receiving FDA Emergency Use Authorization (EUA) for its Lyra real-time reverse-transcriptase polymerase chain reaction (RT-PCR) test for detecting SARS-CoV-2, the virus that causes COVID-19. But that was just the tip of the iceberg.

In May, Quidel won an EUA for its Sofia 2 SARS Antigen FIA rapid point-of-care COVID-19 antigen diagnostic test. The test was built to run on the company's Sofia 2 next-generation immunoassay system. A month later, Quidel received an EUA for running the antigen test on its first-generation Sofia system. 

The company announced in July that the U.S. Department of Health and Human Services plans to buy 2,000 Sofia 2 instruments and 750,000 Sofia SARS Antigen FIA over the next few months for use in nursing homes. Quidel also reported that it obtained a CE Mark for the antigen test, paving the way for marketing it in Europe and other countries that accept the CE Mark. 

Demand for Quidel's systems and tests were even stronger than expected in the second quarter of 2020. In June alone, the company shipped around 1,500 Sofia instruments. 

Quidel's COVID-19 boom overshadows the fact that the company was already successful before the coronavirus outbreak earlier this year. In 2019, Quidel generated revenue of nearly $535 million. Cardiac immunoassay sales contributed roughly half of that total. The company also posted a profit of nearly $73 million.

Despite its big gain so far in 2020, Quidel's valuation isn't scary at all. Its shares trade at a little over 20 times expected earnings.

Better coronavirus stock

I like Novavax's prospects. My view is that NanoFlu will win FDA approval and become a blockbuster over time. I'm not as confident about the chances for Novavax's COVID-19 vaccine candidate. But if it is successful, the biotech stock will have a lot more room to run than Quidel has.

However, I think that Quidel is the safer pick. It has plenty of revenue coming in the door. It's profitable. The COVID-19 outbreak should fuel demand at least through 2021. 

If you're a more aggressive investor, Novavax could be more up your alley. But if you prefer to buy stocks of companies that are making money, Quidel is the better fit. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Quidel. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$18.87 (-10.14%) $-2.13
Quidel Corporation Stock Quote
Quidel Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.